TNF and rheumatoid arthritis: Considering the review of Noort and collegues [28] who described the “good ” and the “bad” sides of non-canonical NF-kappaB signaling in the context of RA, it might be appropriate not to confine the development of NF-kappaB inhibitors to the canonical pathway which is activated in cells expressing receptors for pro-inflammatory molecules like IL-1, TNF-alpha or LPS.